Coronavirus disease 2019 in patients with Behcet's disease: a report of 59 cases in Iran.
Behcet’s disease
COVID-19
Outcome
Vasculitis
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
08
10
2021
accepted:
24
11
2021
revised:
10
11
2021
pubmed:
30
11
2021
medline:
15
3
2022
entrez:
29
11
2021
Statut:
ppublish
Résumé
To present the clinical characteristics, disease course, management, and outcomes of COVID-19 infection in patients with Behcet's disease (BD). In this retrospective cohort study, we retrieved BD patients with definite diagnosis of COVID-19 infection. Demographic data, comorbidities, features related both to BD and COVID-19 infection, treatments, and outcomes were collected. Comparisons between patients with or without hospitalization were performed. All statistical analyzes were performed using SPSS version 25. We considered p < 0.05 statistically significant. We identified 61 episodes of COVID-19 infection in 59 BD patients. The prevalence was 0.69%. The median age was 45 years (IQR = 20), and the median disease duration was 162 months (IQR = 195). BD features were similar except for higher rate of arterial involvement and positive pathergy test in infected patients. Thirty-five episodes (62.5%) happened in non-active patients; 39% had a comorbid disease. COVID manifestations were the same as the general population. Flu-like symptoms were the most common (85%), followed by fever (66%), ageusia/anosmia (56%), headache (51%), and pulmonary involvement (48%). There was no change in BD symptoms in 74%. Fifteen patients (25.4%) were hospitalized, and one patient (1.7%) died. Receiving glucocorticoids (p < 0.03) and cytotoxic drugs (p < 0.02) were associated with an increased rate of hospitalization. The incidence of COVID-19 infection in BD patients was not higher than general population in Iran. They showed milder form of disease with lower morbidity and mortality rate. Most were on immunosuppressive drugs, or had a comorbidity apart from BD. No significant effect on BD course was shown. Key Points • The incidence of COVID-19 infection in patients with Behcet's disease is not higher. • They showed milder form of infection with lower morbidity and mortality rate. • No significant effect on Behcet's disease course was shown with COVID19 infection. • BD patients can be managed according to the guidelines used for general population.
Identifiants
pubmed: 34842999
doi: 10.1007/s10067-021-06004-y
pii: 10.1007/s10067-021-06004-y
pmc: PMC8628030
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1177-1183Informations de copyright
© 2021. International League of Associations for Rheumatology (ILAR).
Références
Ann Rheum Dis. 2021 Feb;80(2):e14
pubmed: 32414804
Mod Rheumatol. 2019 Nov;29(6):1023-1030
pubmed: 30557064
Physiol Genomics. 2020 Nov 1;52(11):549-557
pubmed: 32991251
Clin Exp Rheumatol. 2021 Sep-Oct;39 Suppl 132(5):47-50
pubmed: 34128795
Ann Rheum Dis. 2020 Sep 7;:
pubmed: 32895235
Ann Rheum Dis. 2021 Mar;80(3):e41
pubmed: 32719040
Ann Rheum Dis. 2021 Jan 27;:
pubmed: 33504478
Ann Rheum Dis. 2020 Sep;79(9):1170-1173
pubmed: 32532753
Ann Rheum Dis. 2021 Feb;80(2):e18
pubmed: 32321723
Int J Rheum Dis. 2020 Nov;23(11):1541-1549
pubmed: 32940963
J Eur Acad Dermatol Venereol. 2021 Sep;35(9):e541-e543
pubmed: 33914986
Dermatol Ther. 2020 Nov;33(6):e14063
pubmed: 32710599
Intern Emerg Med. 2020 Nov;15(8):1567-1571
pubmed: 32647946
J Thromb Thrombolysis. 2021 Feb;51(2):339-348
pubmed: 32981005
Clin Infect Pract. 2020 Oct;7:100041
pubmed: 32924007
Arthritis Rheumatol. 2020 Dec;72(12):1981-1989
pubmed: 32725762
N Engl J Med. 2020 Oct 29;383(18):1757-1766
pubmed: 32329974
J Clin Med. 2021 Feb 05;10(4):
pubmed: 33562758
Ann Rheum Dis. 2020 Sep;79(9):1156-1162
pubmed: 32457048
Ann Rheum Dis. 2020 Jun;79(6):839-840
pubmed: 32205336
Ann Rheum Dis. 2021 May;80(5):e62
pubmed: 32546603
Ann Rheum Dis. 2020 Aug;79(8):1007-1013
pubmed: 32444415
Ann Rheum Dis. 2020 Jul;79(7):859-866
pubmed: 32471903
Eur Rev Med Pharmacol Sci. 2020 Sep;24(18):9695-9697
pubmed: 33015814
Semin Arthritis Rheum. 2020 Aug;50(4):564-570
pubmed: 32425260
N Engl J Med. 2020 Jul 2;383(1):85-88
pubmed: 32348641
Arthritis Rheum. 2013 Jan;65(1):1-11
pubmed: 23045170
Hematol Oncol Stem Cell Ther. 2020 Jul 6;:
pubmed: 32645300
Curr Opin Rheumatol. 2021 Mar 1;33(2):155-162
pubmed: 33332890
Lancet. 1990 May 5;335(8697):1078-80
pubmed: 1970380
Ann Rheum Dis. 2021 May;80(5):660-666
pubmed: 33257496
J Eur Acad Dermatol Venereol. 2014 Mar;28(3):338-47
pubmed: 23441863
Ann Rheum Dis. 2021 Apr;80(4):527-538
pubmed: 33268442